Business context and reporting period
Exelixis, Inc. is an oncology-focused biotechnology company whose commercial business centers on cabozantinib products, principally CABOMETYX. This is a Form 10-Q for the first quarter of 2021: the filing identifies the quarter as ended April 2, 2021, while the financial statements are presented for the three months ended March 31, 2021. The supplied request metadata says “2020 Q1,” which does not match the filing; the comparison period is the first quarter of 2020.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Total revenue | $270.2 million | $226.9 million; up 19% |
| Net product revenue | $227.2 million | $193.9 million; up 17% |
| Operating income (loss) | $(4.6) million | $52.8 million |
| Net income | $1.6 million | $48.6 million |
| Basic / diluted earnings per share | $0.01 / $0.00 | $0.16 / $0.15 |
| Operating cash flow | $39.5 million | $56.1 million |
| Cash, cash equivalents, restricted cash and investments | $1.6 billion at March 31, 2021 | $1.5 billion at December 31, 2020 |
CABOMETYX net product revenue was $223.6 million, up 18%; COMETRIQ revenue was $3.6 million, down 22%. Gross margin was 94%, versus 95%. Research and development expense rose 56% to $159.3 million, and selling, general and administrative expense rose 63% to $102.4 million. Interest income declined to $2.7 million from $7.2 million. A $3.6 million income tax benefit contributed to reported net income despite a pre-tax loss.
At March 31, 2021, total assets were $2.19 billion, current assets $1.43 billion, and current liabilities $213.3 million. The filing reports no material off-balance-sheet arrangements and does not list debt on the balance sheet. Management said available resources and expected revenues should fund operations for at least 12 months after filing.
Material changes versus the prior comparable period
- Revenue growth reflected higher CABOMETYX unit sales, including uptake after the January 2021 U.S. approval of CABOMETYX with OPDIVO as first-line treatment for advanced renal cell carcinoma, plus higher collaboration and royalty revenue.
- Operating results weakened sharply as expenses grew faster than revenue. R&D increases included clinical-trial spending, personnel, and licensing and collaboration costs; SG&A increases included launch marketing and stock-based compensation.
- Stock-based compensation increased to $34.7 million from $14.0 million, including expense related to performance-based awards becoming probable of achievement.
- Operating cash flow decreased by $16.5 million year over year, primarily due to higher cash paid for operating expenses, partly offset by favorable working-capital movements.
- Cash and investments increased from year-end, while $48.2 million of short-term investments was restricted as collateral for a letter of credit tied to campus tenant improvements.
Outlook, commentary, risks and contingencies
- Management expected net product revenue to increase during the rest of 2021 versus the comparable prior-year period, driven mainly by CABOMETYX growth following the OPDIVO combination approval and a higher selling price. It also anticipated a higher discount-and-allowance rate.
- Management expected license revenue to decline versus 2020 due to fewer anticipated milestones, partly offset by royalties, and collaboration services revenue to potentially decline because of lower expected development-cost reimbursements.
- R&D and SG&A expenses were expected to continue increasing in 2021. Management said gross margin was not expected to change significantly.
- Clinical catalysts included anticipated second-quarter 2021 top-line results from COSMIC-312, planned 2021 regulatory filings contingent on supportive data, and expected 2022 top-line results from COSMIC-313. Timelines and outcomes are uncertain.
- COVID-19 had a modest reported impact through the filing date, but could still disrupt trials, discovery work, commercial activity, or supply. The company reported no material supply-chain impairment to date.
- Generic competition is a significant risk. MSN’s CABOMETYX patent litigation was scheduled for a May 2022 bench trial; the company also received a Teva ANDA notice in May 2021. The company said the likelihood and amount of any potential loss could not be estimated.
- The company entered licensing and collaboration agreements with Adagene and WuXi Bio, paying $14.0 million in aggregate upfront and committing to potential development, regulatory and commercial milestones and royalties.
- Other principal risks include clinical-trial and regulatory uncertainty, competition, pricing and reimbursement pressure, dependence on collaboration partners, intellectual-property challenges, and the possibility that expenses outpace revenue.
Important facts for investors to verify
- Confirm the reporting period: the filing is Q1 2021, notwithstanding the request metadata’s Q1 2020 label, and uses April 2 as the fiscal quarter-end reference while statements show March 31.
- Track CABOMETYX sales growth, discount and rebate trends, and adoption of the first-line RCC combination.
- Assess whether rising clinical, commercialization, licensing and stock-compensation costs are supported by revenue growth and cash generation.
- Monitor COSMIC-312 and other clinical or regulatory milestones, including timing and whether results support the company’s stated filing plans.
- Follow the MSN and Teva generic proceedings and the potential effect of early generic entry on CABOMETYX revenue.
- Review liquidity, restricted cash, investment maturities, and the substantial milestone and royalty commitments associated with new pipeline agreements.